Cantor Fitzgerald reiterated their overweight rating on shares of Elutia (NASDAQ:ELUT - Free Report) in a research note issued to investors on Friday morning,Benzinga reports. Cantor Fitzgerald currently has a $8.00 target price on the stock.
Elutia Price Performance
Shares of Elutia stock traded down $0.28 during trading on Friday, hitting $2.72. The company's stock had a trading volume of 32,722 shares, compared to its average volume of 38,481. The stock has a 50-day moving average price of $3.08 and a two-hundred day moving average price of $3.63. Elutia has a 52 week low of $2.28 and a 52 week high of $5.24. The stock has a market cap of $94.01 million, a price-to-earnings ratio of -1.04 and a beta of 0.86.
Institutional Trading of Elutia
A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of Elutia by 50.3% during the 3rd quarter. Geode Capital Management LLC now owns 188,408 shares of the company's stock valued at $718,000 after purchasing an additional 63,047 shares in the last quarter. Arcus Capital Partners LLC raised its holdings in Elutia by 100.0% during the third quarter. Arcus Capital Partners LLC now owns 20,000 shares of the company's stock worth $76,000 after buying an additional 10,000 shares during the last quarter. Millennium Management LLC increased its position in shares of Elutia by 16.4% during the fourth quarter. Millennium Management LLC now owns 45,217 shares of the company's stock worth $169,000 after acquiring an additional 6,386 shares in the last quarter. Citadel Advisors LLC bought a new stake in Elutia during the 4th quarter worth approximately $84,000. Finally, Northern Trust Corp raised its stake in shares of Elutia by 30.0% in the fourth quarter. Northern Trust Corp now owns 17,957 shares of the company's stock worth $67,000 after purchasing an additional 4,148 shares during the last quarter. 74.03% of the stock is currently owned by institutional investors and hedge funds.
About Elutia
(
Get Free Report)
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
Further Reading
Before you consider Elutia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elutia wasn't on the list.
While Elutia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
